Cytokind

Executive Summary

Cytokind is a San Diego-based biotechnology company focused on developing and commercializing prescription Narrowband Ultraviolet B (NB-UVB) phototherapy devices for home use. The company leverages light therapy to modulate the immune system, targeting autoimmune diseases, chronic skin conditions, and related inflammatory disorders. By providing a non-drug, clinically-supported treatment option accessible outside traditional dermatology clinics, Cytokind aims to address the significant unmet need for convenient, effective, and safe home-based phototherapy. The company's core technology is based on decades of clinical evidence supporting NB-UVB for conditions like psoriasis, vitiligo, and atopic dermatitis. Cytokind's devices are designed to be user-friendly, allowing patients to receive prescribed phototherapy in the comfort of their own homes, thereby improving adherence and outcomes.

Upcoming Catalysts (preview)

• Q4 2026FDA 510(k) clearance for expanded indication (e.g., atopic dermatitis)70% success
• Q1 2027Publication of pivotal clinical trial results demonstrating efficacy in a new autoimmune indication60% success
• Q2 2026Strategic partnership with a major dermatology network for distribution50% success